Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 1;16(3):148-151.
doi: 10.1097/COH.0000000000000680.

Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV

Jordan E Lake  1 , Janine Trevillyan  2
Affiliations
Review

Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV

Jordan E Lake et al. Curr Opin HIV AIDS. .

Abstract

Purpose of review: Obesity is increasing in people with HIV (PWH). This review aims to summarise the recent evidence investigating the associations between the use of integrase inhibitors and tenofovir alafenamide (TAF) with weight gain and the mechanisms by which this may occur. Understanding the role that antiretroviral therapies play in promoting weight gain is critical in making informed treatment decisions.

Recent findings: Weight gain is common with antiretroviral therapies and can lead to significant medical complications for PWH. Antiretroviral regimens containing an integrase inhibitor in conjunction with TAF are associated with the greatest degree of weight gain. This weight gain is greatest with dolutegravir and bictegravir compared with other integrase inhibitors. Some of the measured weight gain attributed to TAF may actually reflect a loss of weight suppressant effects of tenofovir disoproxil fumarate, and thus the exact proportional contribution of TAF remains to be seen. The mechanisms by which advent of antiretroviral therapy may be promoting weight gain is still being determined but underlying genetic risks factors and gender are very important determinants of the degree of weight gained.

Summary: Integrase inhibitors and TAF contribute to weight gain in PWH. This places them at risk for potentially serious medical complications.

PubMed Disclaimer

References

    1. Patel P, Rose CE, Collins PY, et al. Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis. AIDS 2018; 32: (Suppl 1): S5–S20.
    1. Yuh B, Tate J, Butt AA, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis 2015; 60:1852–1859.
    1. Norwood J, Turner M, Bofill C, et al. Brief report: weight gain in persons with HIV switched From Efavirenz- based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr 2017; 76:527–531.
    1. Lahiri CD, Xu Y, Wang K, et al. Weight and body mass index change after switching to integrase inhibitors or tenofovir alafenamide among women living with HIV. AIDS Res Hum Retroviruses 2021; [Epub ahead of print].
    1. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med 2019; 381:803–815.

Publication types

LinkOut - more resources